Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis

References

• Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, McCallum RW, Olden KW, Parkman HP, Parrish CR, Prather CM, Softer EE, Twillman R, Vinik AI. (2006). Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 18(4):263–83.
   PubMedGoogle Scholar
• Ahmad N, Keith-Ferris J, Gooden E, Abell T. (2006). Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 6(6):571–6.
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L et al. (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815–32.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Spence JD, Bailey DG. (2000). Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41–57.
   PubMedGoogle Scholar
• Friedenberg FK, Parkman HP. (2007). Advances in the management of gastroparesis. Curr Treat Options Gastroenterol 10(4):283–93.
   PubMedGoogle Scholar
• Galetin A, Burt H, Gibbons L, Houston JB. (2006). Prediction of time-dependent CYP3A4 drug–drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34(1):166–75.
   PubMed Web of Science ®Google Scholar
• Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. (2006). A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro–in vivo extrapolation. Curr Drug Metab 7(3):315–34.
   PubMed Web of Science ®Google Scholar
• Ishii K, Saito Y, Itai S, Nemoto M, Takayama K, Nagai T. (1998). Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. Drug Dev Ind Pharm 24(2):129–37.
   PubMedGoogle Scholar
• McCallum RW, Brown RL. (1998). Diabetic and nondiabetic gastroparesis. Curr Treat Options Gastroenterol 1(1):1–7.
   PubMedGoogle Scholar
• Michaud V, Simard C, Turgeon J. (2007). An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies. J Chromatogr B Analyt Technol Biomed Life Sci 852(1–2):611–16.
   PubMedGoogle Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 35(2):246–55.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 316(1):336–48.
   PubMed Web of Science ®Google Scholar
• Pasricha PJ. (2001). Prokinetic agents, antiemetics, and agents used in irritable bowel syndrome. In: Hardman J, Limbird L, Goodman AG, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw-Hill.
   Google Scholar
• Polasek TM, Miners JO. (2006). Quantitative prediction of macrolide drug–drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 62(3):203–8.
   PubMedGoogle Scholar
• Reddymasu SC, Soykan I, McCallum RW. (2007). Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102(9):2036–45.
   PubMedGoogle Scholar
• Silverman RB. (1995). Mechanism-based enzyme inactivators. Methods Enzymol 249:240–83.
   PubMed Web of Science ®Google Scholar
• Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J. (2004). Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 34(11–12):1013–23.
   PubMedGoogle Scholar
• Smith DS, Ferris CD. (2003). Current concepts in diabetic gastroparesis. Drugs 63(13):1339–58.
   PubMedGoogle Scholar
• Thummel KE, Shen DD. (2001). Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman J, Limbird L, Goodman AG, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw Hill.
   Google Scholar
• Wang YH, Jones DR, Hall SD. (2004). Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32(2):259–66.
   PubMed Web of Science ®Google Scholar
• Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. (2004). Characterization of human cytochrome P450 enzymes catalysing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58(3):277–87.
   PubMedGoogle Scholar
• Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44(3):279–304.
   PubMedGoogle Scholar
• Zhou SF, Xue CC, Yu XQ, Li C, Wang G. (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29(6):687–710.
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9(4):310–22.
   PubMedGoogle Scholar